Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B

Aliment Pharmacol Ther 2010; 32: 1323–1331 Summary Background On‐treatment predictors of response to peginterferon can guide individualization of therapy in chronic hepatitis B virus infection. Aim To investigate the use of serum hepatitis B surface antigen quantification to predict sustained resp...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Alimentary pharmacology & therapeutics 2010-12, Vol.32 (11‐12), p.1323-1331
Hauptverfasser:	Chan, H. L.‐Y., Wong, V. W.‐S., Chim, A. M.‐L., Chan, H.‐Y., Wong, G. L.‐H., Sung, J. J.‐Y.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antiviral Agents - immunology Antiviral Agents - therapeutic use Biological and medical sciences Digestive system DNA Drug Therapy, Combination Female Gastroenterology. Liver. Pancreas. Abdomen hepatitis B e antigen Hepatitis B e Antigens - blood Hepatitis B e Antigens - immunology Hepatitis B surface antigen Hepatitis B virus Hepatitis B, Chronic - drug therapy Hepatitis B, Chronic - immunology Human viral diseases Humans Infectious diseases Interferons - therapeutic use Lamivudine Lamivudine - therapeutic use Male Medical sciences Middle Aged Pharmacology. Drug treatments Polyethylene Glycols - therapeutic use Predictive Value of Tests ROC Curve Seroconversion Time Factors Treatment Outcome Viral diseases Viral hepatitis Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Aliment Pharmacol Ther 2010; 32: 1323–1331 Summary Background On‐treatment predictors of response to peginterferon can guide individualization of therapy in chronic hepatitis B virus infection. Aim To investigate the use of serum hepatitis B surface antigen quantification to predict sustained response. Methods Hepatitis B e antigen‐positive chronic hepatitis B patients who received peginterferon for 32–48 weeks with or without lamivudine combination were studied. Sustained response was defined as hepatitis B e antigen seroconversion and chronic hepatitis B virus DNA
ISSN:	0269-2813 1365-2036
DOI:	10.1111/j.1365-2036.2010.04474.x